Skip to main content

Share story

Policy

CISA replaces acting director after a bumbling year on the job

CISA replaces acting director after a bumbling year on the job Image: Primary
The U.S. Cybersecurity and Infrastructure Security Agency has replaced its acting director. Madhu Gottumukkala served as the agency's top boss for a tumultuous year. The move comes after reports of difficulties in his leadership. A CISA spokesperson told TechCrunch that Nick Andersen will replace Gottumukkala as the new acting director. Andersen previously served as the agency's top official overseeing its cybersecurity division. Gottumukkala has been moved to a new position as director of strategic implementation in the Department of Homeland Security. The spokesperson claimed Gottumukkala had done a remarkable job. Reports indicated that Gottumukkala struggled to lead the agency and caused security headaches, including the uploading of sensitive government documents to ChatGPT. Gottumukkala also reportedly failed a counterintelligence polygraph he took in order to view classified documents and suspended several career officials in response, including the agency's then chief security officer. Staffing at the agency was slashed by one third. ABC News first reported Gottumukkala's departure.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from TechCrunch and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.